Published in Cell Microbiol on April 01, 2008
Cryptococcal interactions with the host immune system. Eukaryot Cell (2010) 1.57
Immunoglobulins in defense, pathogenesis, and therapy of fungal diseases. Cell Host Microbe (2012) 1.07
Automated analysis of cryptococcal macrophage parasitism using GFP-tagged cryptococci. PLoS One (2010) 0.97
Antibody binding to Cryptococcus neoformans impairs budding by altering capsular mechanical properties. J Immunol (2012) 0.87
Rare Cryptococus gattii infection in an immunocompetent dairy goat following a cesarean section. Med Mycol Case Rep (2012) 0.81
Fungal serotype-specific differences in bacterial-yeast interactions. Virulence (2015) 0.80
Surfactant protein D facilitates Cryptococcus neoformans infection. Infect Immun (2012) 0.78
Dancing cheek to cheek: Cryptococcus neoformans and phagocytes. Springerplus (2015) 0.78
Variability of phenotypic traits in Cryptococcus varieties and species and the resulting implications for pathogenesis. Future Microbiol (2010) 0.78
Reticulum cell sarcoma: an effector cell in antibody-dependent cell-mediated immunity. J Immunol (1975) 7.00
Epidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Australasian Cryptococcal Study Group. Clin Infect Dis (2000) 3.71
Cryptococcus neoformans is a facultative intracellular pathogen in murine pulmonary infection. Infect Immun (2000) 3.42
Cryptococcus neoformans interactions with amoebae suggest an explanation for its virulence and intracellular pathogenic strategy in macrophages. Proc Natl Acad Sci U S A (2001) 3.37
Intracellular parasitism of macrophages by Cryptococcus neoformans. Trends Microbiol (2001) 3.34
Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection. J Infect Dis (1992) 2.98
Phagosome extrusion and host-cell survival after Cryptococcus neoformans phagocytosis by macrophages. Curr Biol (2006) 2.92
Replication of Cryptococcus neoformans in macrophages is accompanied by phagosomal permeabilization and accumulation of vesicles containing polysaccharide in the cytoplasm. Proc Natl Acad Sci U S A (2002) 2.68
Expulsion of live pathogenic yeast by macrophages. Curr Biol (2006) 2.65
Cryptococcus neoformans infections at Vancouver Hospital and Health Sciences Centre (1997-2002): epidemiology, microbiology and histopathology. J Med Microbiol (2004) 2.38
Multiple gene genealogies reveal recent dispersion and hybridization in the human pathogenic fungus Cryptococcus neoformans. Mol Ecol (2000) 2.30
Protective and nonprotective monoclonal antibodies to Cryptococcus neoformans originating from one B cell. J Exp Med (1995) 2.11
Molecular characterization of the humoral responses to Cryptococcus neoformans infection and glucuronoxylomannan-tetanus toxoid conjugate immunization. J Exp Med (1993) 2.09
Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages. Infect Immun (1995) 2.09
Role of the capsule in phagocytosis of Cryptococcus neoformans. Rev Infect Dis (1988) 2.03
Cryptococcus neoformans gene expression during murine macrophage infection. Eukaryot Cell (2005) 1.89
CR3 (CD11b/CD18) and CR4 (CD11c/CD18) are involved in complement-independent antibody-mediated phagocytosis of Cryptococcus neoformans. Immunity (2002) 1.83
Variation in the structure of glucuronoxylomannan in isolates from patients with recurrent cryptococcal meningitis. Infect Immun (1995) 1.70
Isotype switching from IgG3 to IgG1 converts a nonprotective murine antibody to Cryptococcus neoformans into a protective antibody. J Immunol (1995) 1.67
Cell-to-cell spread and massive vacuole formation after Cryptococcus neoformans infection of murine macrophages. BMC Immunol (2007) 1.51
The efficacy of complement-mediated phagocytosis of Cryptococcus neoformans is dependent on the location of C3 in the polysaccharide capsule and involves both direct and indirect C3-mediated interactions. Eur J Immunol (2003) 1.45
In vitro response of murine alveolar and peritoneal macrophages to Mycobacterium intracellulare. Am Rev Respir Dis (1983) 1.44
Cryptococcus neoformans in tropical northern Australia: predominantly variant gattii with good outcomes. Aust N Z J Med (1993) 1.41
Spatial and temporal sequence of capsule construction in Cryptococcus neoformans. Mol Microbiol (2001) 1.29
Characterization of Cu,Zn superoxide dismutase (SOD1) gene knock-out mutant of Cryptococcus neoformans var. gattii: role in biology and virulence. Mol Microbiol (2003) 1.23
Clinical and environmental isolates of Cryptococcus gattii from Australia that retain sexual fecundity. Eukaryot Cell (2005) 1.18
Opsonic requirements for dendritic cell-mediated responses to Cryptococcus neoformans. Infect Immun (2005) 1.17
Fc-dependent and Fc-independent opsonization of Cryptococcus neoformans by anticapsular monoclonal antibodies: importance of epitope specificity. Infect Immun (2002) 1.16
Opsonization and phagocytosis of Cryptococcus neoformans. Arch Med Res (1993) 1.11
First identification of autochthonous Cryptococcus neoformans var. gattii isloated from goats with predominantly severe pulmonary disease in Spain. J Clin Microbiol (1998) 1.07
Age effects on macrophage function vary by tissue site, nature of stimulant, and exercise behavior. Exp Gerontol (2004) 1.00
Dependence of macrophage phagocytic efficacy on antibody concentration. Infect Immun (2007) 0.94
Genomic organization and expression of 23 new genes from MATalpha locus of Cryptococcus neoformans var. gattii. Biochem Biophys Res Commun (2005) 0.89
Cryptococcosis outbreak in psittacine birds in Brazil. Med Mycol (2004) 0.89
First reported isolation of Cryptococcus neoformans var. gattii from a patient in Singapore. J Clin Microbiol (2002) 0.84
Fungicidal activity of murine broncho-alveolar macrophages against Blastomyces dermatitidis. J Med Microbiol (1986) 0.84
Characterization of a flocculation-like phenotype in Cryptococcus neoformans and its effects on pathogenesis. Cell Microbiol (2006) 0.83
Misconduct accounts for the majority of retracted scientific publications. Proc Natl Acad Sci U S A (2012) 5.89
Causes for the persistence of impact factor mania. MBio (2014) 3.77
Why has the number of scientific retractions increased? PLoS One (2013) 3.59
Retracted science and the retraction index. Infect Immun (2011) 3.35
The contribution of melanin to microbial pathogenesis. Cell Microbiol (2003) 3.12
Cryptococcosis. Infect Dis Clin North Am (2002) 3.01
Phagosome extrusion and host-cell survival after Cryptococcus neoformans phagocytosis by macrophages. Curr Biol (2006) 2.92
Replication of Cryptococcus neoformans in macrophages is accompanied by phagosomal permeabilization and accumulation of vesicles containing polysaccharide in the cytoplasm. Proc Natl Acad Sci U S A (2002) 2.68
Vesicular polysaccharide export in Cryptococcus neoformans is a eukaryotic solution to the problem of fungal trans-cell wall transport. Eukaryot Cell (2006) 2.55
Public health and biosecurity. Adaptations of avian flu virus are a cause for concern. Science (2012) 2.52
Extracellular vesicles produced by Cryptococcus neoformans contain protein components associated with virulence. Eukaryot Cell (2007) 2.42
NIH peer review reform--change we need, or lipstick on a pig? Infect Immun (2009) 2.21
Impact of melanin on microbial virulence and clinical resistance to antimicrobial compounds. Antimicrob Agents Chemother (2006) 2.12
The physical properties of the capsular polysaccharides from Cryptococcus neoformans suggest features for capsule construction. J Biol Chem (2005) 2.07
Fungal cell gigantism during mammalian infection. PLoS Pathog (2010) 2.04
Superoxide dismutase influences the virulence of Cryptococcus neoformans by affecting growth within macrophages. Infect Immun (2003) 2.00
The capsule of the fungal pathogen Cryptococcus neoformans. Adv Appl Microbiol (2009) 1.97
Induction of capsule growth in Cryptococcus neoformans by mammalian serum and CO(2). Infect Immun (2003) 1.89
Reforming science: methodological and cultural reforms. Infect Immun (2011) 1.85
The origin and maintenance of virulence for the human pathogenic fungus Cryptococcus neoformans. Microbes Infect (2003) 1.84
CR3 (CD11b/CD18) and CR4 (CD11c/CD18) are involved in complement-independent antibody-mediated phagocytosis of Cryptococcus neoformans. Immunity (2002) 1.83
More is not necessarily better: prozone-like effects in passive immunization with IgG. J Immunol (2003) 1.81
Mycobacteria release active membrane vesicles that modulate immune responses in a TLR2-dependent manner in mice. J Clin Invest (2011) 1.80
An insight into the antifungal pipeline: selected new molecules and beyond. Nat Rev Drug Discov (2010) 1.78
Nontoxic radioactive Listeria(at) is a highly effective therapy against metastatic pancreatic cancer. Proc Natl Acad Sci U S A (2013) 1.76
Vesicular transport in Histoplasma capsulatum: an effective mechanism for trans-cell wall transfer of proteins and lipids in ascomycetes. Cell Microbiol (2008) 1.73
Ionizing radiation delivered by specific antibody is therapeutic against a fungal infection. Proc Natl Acad Sci U S A (2003) 1.71
Ionizing radiation changes the electronic properties of melanin and enhances the growth of melanized fungi. PLoS One (2007) 1.70
Lost in translation--basic science in the era of translational research. Infect Immun (2009) 1.70
The immunoglobulin heavy chain constant region affects kinetic and thermodynamic parameters of antibody variable region interactions with antigen. J Biol Chem (2007) 1.67
Cryptococcus neoformans CAP59 (or Cap59p) is involved in the extracellular trafficking of capsular glucuronoxylomannan. Eukaryot Cell (2004) 1.64
The presence of female conveners correlates with a higher proportion of female speakers at scientific symposia. MBio (2014) 1.63
Self-aggregation of Cryptococcus neoformans capsular glucuronoxylomannan is dependent on divalent cations. Eukaryot Cell (2007) 1.63
Bacillus anthracis produces membrane-derived vesicles containing biologically active toxins. Proc Natl Acad Sci U S A (2010) 1.62
Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis. Antimicrob Agents Chemother (2005) 1.61
An innate immune system cell is a major determinant of species-related susceptibility differences to fungal pneumonia. J Immunol (2005) 1.61
Antibodies to a cell surface histone-like protein protect against Histoplasma capsulatum. J Clin Invest (2003) 1.60
Important science--it's all about the SPIN. Infect Immun (2009) 1.59
A requirement for FcγR in antibody-mediated bacterial toxin neutralization. J Exp Med (2010) 1.58
Ionizing radiation: how fungi cope, adapt, and exploit with the help of melanin. Curr Opin Microbiol (2008) 1.58
Melanization of Cryptococcus neoformans and Histoplasma capsulatum reduces their susceptibilities to amphotericin B and caspofungin. Antimicrob Agents Chemother (2002) 1.57
Global warming will bring new fungal diseases for mammals. MBio (2010) 1.56
Exploiting amoeboid and non-vertebrate animal model systems to study the virulence of human pathogenic fungi. PLoS Pathog (2007) 1.55
Policy: Adaptations of avian flu virus are a cause for concern. Nature (2012) 1.54
Experimental modulation of capsule size in Cryptococcus neoformans. Biol Proced Online (2004) 1.52
Vertebrate endothermy restricts most fungi as potential pathogens. J Infect Dis (2009) 1.51
Cell-to-cell spread and massive vacuole formation after Cryptococcus neoformans infection of murine macrophages. BMC Immunol (2007) 1.51
Capsule enlargement in Cryptococcus neoformans confers resistance to oxidative stress suggesting a mechanism for intracellular survival. Cell Microbiol (2008) 1.50
Susceptibility of the human pathogenic fungi Cryptococcus neoformans and Histoplasma capsulatum to gamma-radiation versus radioimmunotherapy with alpha- and beta-emitting radioisotopes. J Nucl Med (2004) 1.47
Interaction of radiolabeled antibodies with fungal cells and components of the immune system in vitro and during radioimmunotherapy for experimental fungal infection. J Infect Dis (2006) 1.47
Monoclonal antibody-based therapies for microbial diseases. Vaccine (2009) 1.47
Sec6-dependent sorting of fungal extracellular exosomes and laccase of Cryptococcus neoformans. Mol Microbiol (2008) 1.46
Synthesis and assembly of fungal melanin. Appl Microbiol Biotechnol (2011) 1.45
The efficacy of complement-mediated phagocytosis of Cryptococcus neoformans is dependent on the location of C3 in the polysaccharide capsule and involves both direct and indirect C3-mediated interactions. Eur J Immunol (2003) 1.45
Cryptococcus neoformans capsular polysaccharide and exopolysaccharide fractions manifest physical, chemical, and antigenic differences. Eukaryot Cell (2007) 1.45
Cryptococcus neoformans virulence is enhanced after growth in the genetically malleable host Dictyostelium discoideum. Infect Immun (2003) 1.44
The effect of L-DOPA on Cryptococcus neoformans growth and gene expression. Virulence (2011) 1.42
Susceptibility of Cryptococcus neoformans biofilms to antifungal agents in vitro. Antimicrob Agents Chemother (2006) 1.42
Specific antibody can prevent fungal biofilm formation and this effect correlates with protective efficacy. Infect Immun (2005) 1.42
Microstructure of cell wall-associated melanin in the human pathogenic fungus Cryptococcus neoformans. Biochemistry (2005) 1.40
Extracellular vesicles from Cryptococcus neoformans modulate macrophage functions. Infect Immun (2010) 1.40
Experimental murine cryptococcal infection results in contamination of bedding with Cryptococcus neoformans. Contemp Top Lab Anim Sci (2003) 1.40
Capsule structural heterogeneity and antigenic variation in Cryptococcus neoformans. Eukaryot Cell (2007) 1.39
Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins. PLoS Med (2006) 1.38
A monoclonal antibody to Bacillus anthracis protective antigen defines a neutralizing epitope in domain 1. Infect Immun (2006) 1.38
The polysaccharide capsule of the pathogenic fungus Cryptococcus neoformans enlarges by distal growth and is rearranged during budding. Mol Microbiol (2006) 1.37
Fc gamma receptors regulate immune activation and susceptibility during Mycobacterium tuberculosis infection. J Immunol (2008) 1.36
Binding of the wheat germ lectin to Cryptococcus neoformans suggests an association of chitinlike structures with yeast budding and capsular glucuronoxylomannan. Eukaryot Cell (2007) 1.36
Reforming science: structural reforms. Infect Immun (2011) 1.36
The radioprotective properties of fungal melanin are a function of its chemical composition, stable radical presence and spatial arrangement. Pigment Cell Melanoma Res (2008) 1.36
The capsular dynamics of Cryptococcus neoformans. Trends Microbiol (2006) 1.35
Cryptococcus neoformans {alpha} strains preferentially disseminate to the central nervous system during coinfection. Infect Immun (2005) 1.33
The immunoglobulin constant region contributes to affinity and specificity. Trends Immunol (2008) 1.32
Histoplasma capsulatum synthesizes melanin-like pigments in vitro and during mammalian infection. Infect Immun (2002) 1.31
Vesicle-associated melanization in Cryptococcus neoformans. Microbiology (2009) 1.31
Isotype can affect the fine specificity of an antibody for a polysaccharide antigen. J Immunol (2002) 1.30
Neutropenia alters lung cytokine production in mice and reduces their susceptibility to pulmonary cryptococcosis. Eur J Immunol (2003) 1.30
The relative susceptibility of mouse strains to pulmonary Cryptococcus neoformans infection is associated with pleiotropic differences in the immune response. Infect Immun (2007) 1.30
Mechanistic science. Infect Immun (2009) 1.29
Cryptococcus neoformans capsular enlargement and cellular gigantism during Galleria mellonella infection. PLoS One (2011) 1.29
Antibody-mediated immunity against tuberculosis: implications for vaccine development. Cell Host Microbe (2013) 1.26
Dead cells in melanoma tumors provide abundant antigen for targeted delivery of ionizing radiation by a mAb to melanin. Proc Natl Acad Sci U S A (2004) 1.26
Immunoglobulin G monoclonal antibodies to Cryptococcus neoformans protect mice deficient in complement component C3. Infect Immun (2002) 1.24
Characterization of yeast extracellular vesicles: evidence for the participation of different pathways of cellular traffic in vesicle biogenesis. PLoS One (2010) 1.24
Cryptococcus neoformans capsular polysaccharide component galactoxylomannan induces apoptosis of human T-cells through activation of caspase-8. Cell Microbiol (2006) 1.22
Males are overrepresented among life science researchers committing scientific misconduct. MBio (2013) 1.22
Radial mass density, charge, and epitope distribution in the Cryptococcus neoformans capsule. Eukaryot Cell (2006) 1.21
Estimating the relative contributions of virulence factors for pathogenic microbes. Infect Immun (2006) 1.21
Quorum sensing in fungi--a review. Med Mycol (2012) 1.21
Variable-region-identical antibodies differing in isotype demonstrate differences in fine specificity and idiotype. J Immunol (2005) 1.20
Synthesis of melanin-like pigments by Sporothrix schenckii in vitro and during mammalian infection. Infect Immun (2003) 1.19
Bioterrorism: lessons learned since the anthrax mailings. MBio (2011) 1.19
Capsule of Cryptococcus neoformans grows by enlargement of polysaccharide molecules. Proc Natl Acad Sci U S A (2009) 1.19
Cryptococcus neoformans biofilm formation depends on surface support and carbon source and reduces fungal cell susceptibility to heat, cold, and UV light. Appl Environ Microbiol (2007) 1.18
Treating cancer as an infectious disease--viral antigens as novel targets for treatment and potential prevention of tumors of viral etiology. PLoS One (2007) 1.17
Galactoxylomannan does not exhibit cross-reactivity in the platelia Aspergillus enzyme immunoassay. Clin Vaccine Immunol (2007) 1.17
The polysaccharide capsule of Cryptococcus neoformans interferes with human dendritic cell maturation and activation. J Leukoc Biol (2003) 1.17
Antibody efficacy in murine pulmonary Cryptococcus neoformans infection: a role for nitric oxide. J Immunol (2002) 1.16
Ab binding alters gene expression in Cryptococcus neoformans and directly modulates fungal metabolism. J Clin Invest (2010) 1.16